New hope for older blood cancer patients: smarter transplants aim to cut relapse
NCT ID NCT04217278
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with standard therapy, and also tests different conditioning regimens before transplant based on age. Around 333 participants are being followed for at least two years to see which approach works best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vyxeos, Fludarabine, Busulphan, Thiotepa, Cytarabine
What this could lead to
If successful, this could lead to better survival and lower relapse rates for older adults with AML or high-risk MDS after stem cell transplant.
What could go wrong
This is a mid-stage trial with 333 participants, and results may not apply to all patients. Transplants carry serious side effects, and the new therapies might not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Churchill Hospital
Oxford, United Kingdom
-
Derriford Hospital
Plymouth, United Kingdom
-
Freeman Hospital
Newcastle, United Kingdom
-
Hammersmith Hospital
London, United Kingdom
-
King's College Hospital
London, United Kingdom
-
Leicester Royal Infirmary
Leicester, United Kingdom
-
Manchester Royal Infirmary
Manchester, United Kingdom
-
Nottingham City Hospital
Nottingham, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, United Kingdom
-
Queen Elizabeth Hospital Glasgow
Glasgow, United Kingdom
-
St James' University Hospital
Leeds, United Kingdom
-
University Hospital of Wales
Cardiff, United Kingdom
-
University Hospitals Bristol
Bristol, United Kingdom